Johnson & Johnson MedTech launches CEREGLIDE 92 Catheter System for Acute ischemic stroke
Irvine: Johnson & Johnson MedTech, an emerging leader in neurovascular care, has announced the launch of the CEREGLIDE 92 Catheter System, a next-generation .092' catheter with the INNERGLIDE 9 delivery aid, indicated for use in facilitating the insertion and guidance of interventional devices in the neurovascular system.
CEREGLIDE 92 is a .092" inner diameter catheter system that allows physicians to achieve large distal access and is designed to provide flow reduction in the M1 when inserting devices for the revascularization of patients with acute ischemic stroke. The larger lumen also provides distal support for multiple neurovascular tools when treating aneurysms and other hemorrhagic complications. CEREGLIDE 92 is the latest catheter in Johnson & Johnson MedTech’s growing catheter portfolio designed to integrate with Stroke Solutions, such as CEREGLIDE 71, PROWLER EX and EMBOTRAP III.
Acute ischemic strokes account for 85% of all strokes worldwide and the M1 territory is the most commonly affected by stroke. By utilizing CEREGLIDE 92 to insert aspiration catheters during thrombectomy procedures, physicians can restore blood flow in the brain by directly withdrawing a blood clot, or inserting a catheter in combination with a stent retriever. While more than half of ischemic stroke patients treated with mechanical thrombectomy regain functional independence, some patients are left untreated or suffer poor outcomes due to access challenges and failures in navigating the complex anatomy of the brain.
CEREGLIDE 92 features design elements including the co-packaged INNERGLIDE 9 Delivery Aid, a .092” inner diameter, full catheter visibility with BRITE-LINE Technology, and TruCourse Technology, which increases distal tip flexibility aiding in catheter trackability. The system tracks to the M1 and provides large distal placement for procedural control along with full catheter visibility under fluoroscopy.
“Vessel tortuosity and other anatomical challenges are present in approximately 50 percent of mechanical thrombectomy cases, which can increase procedure time or prevent ability to treat,” said Dr. Brian Jankowitz, Chief of Neurosurgery and Co-Chair of the Stroke and Neurovascular Program at the Hackensack Meridian Neuroscience Institute at JFK University Medical Center. “As an early user of CEREGLIDE 92 and INNERGLIDE 9, this super large-bore catheter system helps provide quick and seamless access to the M1 with the benefit of flow control, allowing us to rapidly reperfuse the patient and extend the benefits of next generation stroke technology to more patients.”
Devices within Johnson & Johnson MedTech’s Neurovascular portfolio are developed using expert stroke science insights from the Neuro Thromboembolic Initiative (NTI). The result is devices that have been tested in models that recreate real-world scenarios and seek to further address clinical unmet need.
“Johnson & Johnson MedTech is continuing to innovate to help address the access challenges physicians face during mechanical thrombectomy procedures with the launch of CEREGLIDE™ 92,” said Mark Dickinson, Worldwide President, Neurovascular, Johnson & Johnson MedTech. “The CEREGLIDE™ 92 Catheter System is the latest innovation in our CEREGLIDE and ischemic stroke suite of technologies designed to assist physicians in treating their patients and maximizing procedural outcomes, to ultimately change the trajectory of stroke.”
"The CEREGLIDE 92 Catheter System will utilize electronic instructions for use (e-IFUs). E-IFUs are expected to help reduce Johnson & Johnson MedTech’s environmental footprint, lower CO2 emissions caused during shipment and facilitate a reduction in healthcare systems’ post-consumer recycling and medical waste disposal," the Company stated.
The CEREGLIDE 92 Catheter System is now commercially available in the U.S.
